ATATcH Alternating Treatment Plans for Advanced Cancer
Recruiting now · Phase 2
Conditions studied: Head and Neck Cancer, Lung Cancer
In brief
The purpose of the research is to evaluate a new schedule of alternating cycles of induction chemoimmunotherapy (chemotherapy plus pembrolizumab) and immunotherapy (pembrolizumab) alone for the initial treatment of patients with advanced lung or head and neck cancers.
Key facts
- Study ID
- NCT05358548
- Run by
- Rutgers, The State University of New Jersey
- People needed
- 150
- Starts
- 2022-04-28
- Expected to finish
- 2028-05-01
- Last updated by the study team
- 2026-04-30
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- RWJBarnabas Health - Community Medical Center — Toms River, New Jersey, United States (enrolling)
- Cancer Institute of New Jersey at Hamilton — Hamilton, New Jersey, United States (enrolling)
- RWJBarnabas Health - Jersey City — Jersey City, New Jersey, United States (enrolling)
- RWJBarnabas Health - Monmouth Medical Center Southern Campus — Lakewood, New Jersey, United States (enrolling)
- RWJBarnabas Health - Saint Barnabas Medical Center — Livingston, New Jersey, United States (enrolling)
- RWJBarnabas Health - Monmouth Medical Center — Long Branch, New Jersey, United States (enrolling)
- Trinitas Hospital and Comprehensive Cancer Center — Elizabeth, New Jersey, United States (enrolling)
- Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey, United States (enrolling)
- RWJBarnabas Health - Newark Beth Israel Medical Center — Newark, New Jersey, United States (enrolling)
- Robert Wood Johnson Somerset Hospital — Somerville, New Jersey, United States (enrolling)
- RWJ Barnabas Health - Robert Wood Johnson University Hospital — New Brunswick, New Jersey, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.